Ashford (AINC) Competitors

Lichen China (NASDAQ:LICN) and Ashford (NYSEAMERICAN:AINC) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.

Does the media favor LICN or AINC?

In the previous week, Lichen China had 1 more articles in the media than Ashford. MarketBeat recorded 2 mentions for Lichen China and 1 mentions for Ashford. Ashford's average media sentiment score of 0.34 beat Lichen China's score of 0.00 indicating that Lichen China is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lichen China	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ashford	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of LICN or AINC?

0.2% of Lichen China shares are owned by institutional investors. Comparatively, 13.0% of Ashford shares are owned by institutional investors. 66.7% of Ashford shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is LICN or AINC more profitable?

Ashford has a net margin of 0.01% compared to Ashford's net margin of 0.00%. Ashford's return on equity of 0.00% beat Lichen China's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lichen China	N/A	N/A	N/A
Ashford	0.01%	-17.46%	9.74%

Do analysts rate LICN or AINC?

Ashford has a consensus price target of $13.50, suggesting a potential upside of 105.48%. Given Lichen China's higher possible upside, analysts plainly believe Ashford is more favorable than Lichen China.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lichen China	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Ashford	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has preferable valuation and earnings, LICN or AINC?

Lichen China has higher earnings, but lower revenue than Ashford.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lichen China	$33.81M	0.92	$7.82M	N/A	N/A
Ashford	$644.43M	0.03	$3.65M	-$12.18	-0.54

Does the MarketBeat Community believe in LICN or AINC?

Ashford received 143 more outperform votes than Lichen China when rated by MarketBeat users.

Company	Underperform	Outperform
Lichen China	N/A	N/A
Ashford	Outperform Votes 143 61.64%	Underperform Votes 89 38.36%

Summary

Ashford beats Lichen China on 8 of the 13 factors compared between the two stocks.